Multi-omics Based Prediction of Treatment Response to Immunotherapy Combined with Chemotherapy in Advanced Gastric/Gastroesophageal Junction Cancer.
Predicting Treatment Response to Immunotherapy Combined with Chemotherapy in Advanced Gastric/gastroesophageal Junction Cancer Based on the Multi-omics Information During Tumor Evolution.
Xiangdong Cheng
150 participants
Mar 25, 2024
OBSERVATIONAL
Conditions
Summary
In this project, based on the information of advanced gastric/gastroesophageal junction cancer in evolution under immunotherapy combined with chemotherapy treatment, we will integrate multi-omics dynamic data to identify essential features that correlate to therapeutic effects of immunotherapy therapy, screen potential molecular markers/dominant microbiota for predicting the efficacy of immunotherapy and establish a multimodal predictive model for patients that benefit from immunotherapy. Our project could provide evidence to predict response to immunotherapy for patients with advanced gastric/gastroesophageal junction cancer and potentially optimize the clinical decision-making about therapy for advanced gastric/gastroesophageal junction cancer.
Eligibility
Inclusion Criteria5
- Patients with gastric or gastroesophageal junction adenocarcinoma confirmed by pathology and with advanced or metastatic disease that cannot be resected
- HER2 negative
- Not received any anti-tumor treatment before.
- After evaluation, the treatment plan is chemotherapy combined with immunotherapy.
- Aged 18 to 75 years old, gender is not limited.
Exclusion Criteria7
- Patients with malignant tumors other than gastric cancer or those with tumors metastasized to the stomach from other sites.
- Patients who have previously received anti-tumor treatments such as surgery, radiotherapy and chemotherapy, targeted therapy or immunotherapy.
- Patients with severe infections.
- Those with a history of mental illness cannot cooperate with the research.
- Patients with severe heart, liver, kidney and other diseases.
- Pregnant or lactating patients.
- HER2 positive.
Interventions
Peripheral blood, coating, saliva, and feces on the tongue and clinical data of patients with advanced gastric cancer patients who received chemotherapy combined with immunotherapy will be collected.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06642857